Y-mAbs Therapeutics logo
Y-mAbs Therapeutics YMAB
$ 8.27 -3.56%

Quarterly report 2024-Q3
added 11-08-2024

report update icon

Y-mAbs Therapeutics Income Statement 2011-2024 | YMAB

Annual Income Statement Y-mAbs Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

724 M 134 M 393 M 1.69 B 1.19 B 583 M - - - - - - -

Shares

43.6 M 43.7 M 43.2 M 40.2 M 35.2 M 28.8 M - - - - - - -

Historical Prices

16.6 3.06 9.11 35.2 29.4 21.6 - - - - - - -

Net Income

-21.4 M -95.6 M -55.3 M -119 M -81 M -43.3 M -19.2 M -17.1 M - - - - -

Revenue

84.8 M 65.3 M 34.9 M 20.8 M - - - - - - - - -

Cost of Revenue

11.4 M 7.47 M 2.3 M - - - - - - - - - -

Gross Profit

- - - 18.5 M - - - - - - - - -

Operating Income

-25.7 M -94.8 M -115 M -120 M -83 M -43.2 M -19.2 M - - - - - -

Interest Expense

- - -1.85 M 598 K 1.98 M -44 K 83 K - - - - - -

EBITDA

-24.9 M -94 M -115 M -120 M -82.8 M -43.2 M -19.2 M -17 M - - - - -

Operating Expenses

- - - 138 M 83 M 43.2 M - - - - - - -

General and Administrative Expenses

44.9 M 60.9 M 54.6 M 44.8 M 19.5 M 8.96 M 4.94 M 3.18 M - - - - -

All numbers in USD currency

Quarterly Income Statement Y-mAbs Therapeutics

2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

44.6 M 44 M 43.8 M 43.7 M 43.6 M 43.7 M 43.7 M - 43.7 M 43.7 M 43.7 M 43.7 M 43.6 M 43.6 M 41.9 M - 40.2 M 40 M 39.8 M - 34.4 M 34.2 M 34.2 M 34.2 M 27.3 M 26.7 M 26.7 M - 17.9 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-7 M -9.25 M -6.63 M - -7.75 M -6.3 M -6.39 M - -27.5 M -41.1 M -28.1 M - -28.9 M -22.9 M 33.4 M -19.9 M -32.8 M -40.4 M -26.2 M -23.1 M -23.9 M -18 M -15.9 M -14.1 M -11.4 M -10.3 M -7.48 M -9.25 M -3.83 M -3.19 M -2.89 M - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

18.5 M 22.8 M 19.9 M - 20.5 M 20.8 M 20.3 M - 12.5 M 10.8 M 10.5 M - 8.96 M 11 M 5.38 M 20.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

2.25 M 3.01 M 2.1 M - 2.6 M 4.65 M 2.08 M - 2.48 M 1.14 M 1.83 M - 550 K 200 K 93 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-8.57 M -9.79 M -6.91 M - -7.75 M -7.22 M -7.5 M - -26 M -39.9 M -27.7 M - -28.7 M -22.7 M -28.3 M -20.1 M -32.6 M -40.5 M -26.7 M -23.8 M -24.4 M -18.6 M -16.3 M -14.1 M -11.4 M -10.3 M -7.48 M -9.28 M -3.84 M -3.23 M -2.9 M - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - - - - 1.11 M - -1.51 M -1.19 M -373 K - -154 K -225 K -338 K - -191 K 59 K 568 K - 437 K 598 K 319 K - -11 K -47 K -4 K - 15 K - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - -6.75 M - - - -7.32 M - -25.4 M -39.9 M -27.5 M - -28.2 M -22.7 M -28.1 M -20.1 M -32.4 M -40.3 M -26.7 M -23.8 M -24.3 M -18.6 M -16.2 M -14.1 M -11.4 M -10.3 M -7.48 M -9.28 M -3.84 M -3.23 M -2.9 M - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - - - - - - - - - - - - - - - 32.6 M 40.5 M 26.7 M - 24.4 M 18.6 M 16.3 M - 11.4 M 10.3 M 7.48 M - 3.84 M - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

13.6 M 17.2 M 11.4 M - 10.2 M 11.3 M 12.3 M - 13.6 M 23.1 M 13.4 M - 14 M 13.5 M 12 M - 11.6 M 10.4 M 8.12 M - 4.7 M 4.14 M 3.74 M - 2.68 M 1.96 M 1.28 M - 766 K - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency